The Effect of Leflunomide on Cycling and Activation of T-Cells in HIV-1-Infected Participants

Sarah W. Read, Mary DeGrezia, Emily J. Ciccone et al. · 2010

Read The Effect of Leflunomide on Cycling and Activation of T-Cells in HIV-1-Infected Participants by Sarah W. Read, Mary DeGrezia, Emily J. Ciccone et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0011937.txt.

Description

Sarah Read and co-workers tested in 2010 whether an arthritis drug could calm the immune overdrive seen in HIV infection. Even when HIV is controlled, constant immune activation helps drive the disease. Leflunomide, a drug that tempers immune cell growth, was a candidate for lowering that activation.

In a randomized study of HIV-1 infected participants, the team measured how the drug affected T cell cycling and activation. Slowing the churn of T cells could, in principle, reduce the damage activation causes over years. The trial gives an early read on whether repurposing an existing immune drug is a safe and sensible path in HIV care.

Catalog record

CREATORSarah W. Read, Mary DeGrezia, Emily J. Ciccone et al.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE33 KB
LICENSECreative Commons CC0 License
RIGHTSCC0
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0011937

Browse the full library · About the Tower of Babel